Skip to main content
Fig. 5 | BMC Cancer

Fig. 5

From: Usefulness of combined androgen blockade therapy with gonadotropin-releasing hormone antagonist for bone metastatic prostate cancer with pretreatment prostate-specific antigen level ≥ 50 ng/mL

Fig. 5

Kaplan–Meier curves for prostate-specific antigen progression-free survival (PSA-PFS) showed significantly better results in the group undergoing combined androgen blockade therapy with concurrent gonadotropin-releasing hormone antagonist (CAB-antagonist therapy, n = 11) than the group undergoing combined androgen blockade therapy with concurrent gonadotropin-releasing hormone agonist (CAB-agonist therapy, n = 17) in prostate cancer patients with more than six bone metastases (b). There were no differences between the two groups in prostate cancer patients with less than six bone metastases (a)

Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us